Skip to main content

Articles

Page 35 of 39

  1. Maintenance therapy with imatinib during the post-transplant period has been used for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL); however, its efficacy has not been ...

    Authors: Huan Chen, Kai-yan Liu, Lan-ping Xu, Dai-hong Liu, Yu-hong Chen, Xiang-yu Zhao, Wei Han, Xiao-hui Zhang, Yu Wang, Yuan-yuan Zhang, Ya-zhen Qin, Yan-rong Liu and Xiao-jun Huang
    Citation: Journal of Hematology & Oncology 2012 5:29
  2. We have reported promising outcomes using a staged approach, in which bortezomib/thalidomide/dexamethasone was used only in 14 patients with suboptimal response to VAD (vincristine/adriamycin/dexamethasone) be...

    Authors: Chor Sang Chim, Albert Kwok Wai Lie, Eric Yuk Tat Chan, Herman Sung Yu Liu, Ching Wa Lau, Sze Fai Yip, Joycelyn Sim, Thomas Shek-Kong Wan, Edmond Shiu-Kwan Ma, Raymond Liang, Eric Tse and Yok-Lam Kwong
    Citation: Journal of Hematology & Oncology 2012 5:28
  3. Extranodal nasal-type NK/T-cell lymphoma is a rare and severe disease. Considering the rarity of this lymphoma in Europe, we conducted a multicentric retrospective study on nasal-type NK/T cell lymphoma to det...

    Authors: Adrien Chauchet, Anne-Sophie Michallet, Françoise Berger, Isabelle Bedgedjian, Eric Deconinck, Catherine Sebban, Daciana Antal, Hubert Orfeuvre, Bernadette Corront, Tony Petrella, Maya Hacini, Marie Bouteloup, Gilles Salles and Bertrand Coiffier
    Citation: Journal of Hematology & Oncology 2012 5:27
  4. MicroRNA have a central role in normal haematopoiesis and are deregulated in acute myeloid leukaemia (AML). The purpose of the study was to investigate by qRT-PCR the expression of miRNAs involved in myeloid d...

    Authors: Isabella Faraoni, Serena Laterza, Davide Ardiri, Claudia Ciardi, Francesco Fazi and Francesco Lo-Coco
    Citation: Journal of Hematology & Oncology 2012 5:26
  5. Chronic lymphocytic leukemia (CLL) is the rarest adult leukemia in Japan, whereas it is the most common leukemia in the Western world. Recent studies from the United States and Germany suggest a possible etiol...

    Authors: Masayuki Imajoh, Yumiko Hashida, Ayuko Taniguchi, Mikio Kamioka and Masanori Daibata
    Citation: Journal of Hematology & Oncology 2012 5:25
  6. Mycosis fungoides (MF) and Sezary Syndrome (SS) represent the most common subtypes of primary Cutaneous T-cell lymphoma (CTCL). Patients with advanced MF and SS have a poor prognosis leading to an interest in ...

    Authors: Salvia Jain, Jasmine Zain and Owen O’Connor
    Citation: Journal of Hematology & Oncology 2012 5:24
  7. The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-positive acute lymphoid leukemia (Ph + ALL) patients. Resistant T315I clone may be present prior to initiating dasa...

    Authors: Naoto Takahashi, Masatomo Miura, Stuart A Scott, Takenori Niioka and Kenichi Sawada
    Citation: Journal of Hematology & Oncology 2012 5:23
  8. Although the importance of the hematopoietic transcription factor PU.1 in acute myeloid leukemia (AML) has been demonstrated, the expression of PU.1 in acute promyelocytic leukemia (APL) patient samples awaits...

    Authors: Xuehua Zhu, Hui Zhang, Maoxiang Qian, Xujie Zhao, Wentao Yang, Ping Wang, Ji Zhang and Kankan Wang
    Citation: Journal of Hematology & Oncology 2012 5:22
  9. The discovery of CD117 mutation in almost all gastrointestinal stromal tumors (GISTs) marked a milestone. Other spindle cell neoplasms arising from the GI tract including lipoma, schwannoma, hemangioma, leiomy...

    Authors: Gurpreet Lamba, Samir Ambrale, Byung Lee, Ridhi Gupta, Shamudheen M Rafiyath and Delong Liu
    Citation: Journal of Hematology & Oncology 2012 5:21
  10. Approximately 70% of all patients with myelodysplastic syndrome (MDS) present with lower-risk disease. Some of these patients will initially respond to treatment with growth factors to improve anemia but will ...

    Authors: Naomi Galili, Pablo Tamayo, Olga B Botvinnik, Jill P Mesirov, Margarita R Brooks, Gail Brown and Azra Raza
    Citation: Journal of Hematology & Oncology 2012 5:20
  11. Mesenchymal stem cells (MSC) have generated a great amount of enthusiasm over the past decade as a novel therapeutic paradigm for a variety of diseases. Currently, MSC based clinical trials have been conducted...

    Authors: Shihua Wang, Xuebin Qu and Robert Chunhua Zhao
    Citation: Journal of Hematology & Oncology 2012 5:19
  12. Ezatiostat, a glutathione S-transferase P1-1 inhibitor, promotes the maturation of hematopoietic progenitors and induces apoptosis in cancer cells.

    Authors: Azra Raza, Naomi Galili, Deborah Mulford, Scott E Smith, Gail L Brown, David P Steensma, Roger M Lyons, Ralph Boccia, Mikkael A Sekeres, Guillermo Garcia-Manero and Ruben A Mesa
    Citation: Journal of Hematology & Oncology 2012 5:18
  13. Recombinant human arginase (rhArg) has been developed for arginine deprivation therapy in cancer, and is currently under clinical investigation. During pre-clinical evaluation, rhArg has exhibited significant ...

    Authors: Eddy C Hsueh, Stephanie M Knebel, Wai-Hung Lo, Yun-Chung Leung, Paul Ning-Man Cheng and Chung-Tsen Hsueh
    Citation: Journal of Hematology & Oncology 2012 5:17
  14. Tissue factor (TF), an initiator of blood coagulation, participates in cancer progression and metastasis. We recently found that inhibition of MAPK/ERK upregulated both full length TF (flTF) and soluble isofor...

    Authors: Chaoquan Hu, Limin Huang, Caroline Gest, Xiaodong Xi, Anne Janin, Claudine Soria, Hong Li and He Lu
    Citation: Journal of Hematology & Oncology 2012 5:16
  15. Cell division cycle 20 (CDC20) homolog is an anaphase-promoting complex activator that is essential for cell division, but whether its expression in pancreatic ductal adenocarcinoma (PDAC) is significant is un...

    Authors: David Z Chang, Ying Ma, Baoan Ji, Yan Liu, Patrick Hwu, James L Abbruzzese, Craig Logsdon and Huamin Wang
    Citation: Journal of Hematology & Oncology 2012 5:15
  16. Peripheral blood stem cell (PBSC) mobilization, which uses plerixafor (AMD 3100), a newly developed specific inhibitor of the CXCR4 receptor, in combination with granulocyte-colony stimulating factor(G-CSF), h...

    Authors: Kyung Taek Hong, Hyoung Jin Kang, Nam Hee Kim, Min Sun Kim, Ji Won Lee, Hyery Kim, Kyung Duk Park, Hee Young Shin and Hyo Seop Ahn
    Citation: Journal of Hematology & Oncology 2012 5:14
  17. The ASXL1 gene is one of the most frequently mutated genes in malignant myeloid diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic regulation of gene expression. ASXL1 mutations a...

    Authors: Véronique Gelsi-Boyer, Mandy Brecqueville, Raynier Devillier, Anne Murati, Marie-Joelle Mozziconacci and Daniel Birnbaum
    Citation: Journal of Hematology & Oncology 2012 5:12
  18. MicroRNAs (miRNAs) are short non-coding RNAs that are involved in several important biological processes through regulation of genes post-transcriptionally. Carcinogenesis is one of the key biological processe...

    Authors: Oudai Hassan, Aamir Ahmad, Seema Sethi and Fazlul H Sarkar
    Citation: Journal of Hematology & Oncology 2012 5:9
  19. MicroRNAs are small RNA molecules that regulate gene expression and play critical roles in B cell development and malignancy. miRNA expression is important globally, as B cell specific knockouts of Dicer show ...

    Authors: Thilini R Fernando, Norma I Rodriguez-Malave and Dinesh S Rao
    Citation: Journal of Hematology & Oncology 2012 5:7
  20. Aplastic anemia (AA) is characterized by pancytopenia and bone marrow hypoplasia, which results from immune-mediated hematopoiesis suppression. Understanding the pathophysiology of the immune system, particula...

    Authors: Bo Li, Sichu Liu, Yuzhe Niu, Su Fang, Xiuli Wu, Zhi Yu, Shaohua Chen, Lijian Yang and Yangqiu Li
    Citation: Journal of Hematology & Oncology 2012 5:6
  21. Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes encode cytosolic and mitochondrial enzymes that catalyze the conversion of isocitrate to α-ketoglutarate. Acquired somatic mutations of IDH1 and ID...

    Authors: Sadudee Chotirat, Wanna Thongnoppakhun, Orathai Promsuwicha, Chetsada Boonthimat and Chirayu U Auewarakul
    Citation: Journal of Hematology & Oncology 2012 5:5
  22. While lenalidomide (LEN) shows high efficacy in myelodysplastic syndromes (MDS) with del[5q], responses can be also seen in patients presenting without del[5q]. We hypothesized that improved detection of chrom...

    Authors: Yuka Sugimoto, Mikkael A Sekeres, Hideki Makishima, Fabiola Traina, Valeria Visconte, Anna Jankowska, Andres Jerez, Hadrian Szpurka, Christine L O'Keefe, Kathryn Guinta, Manuel Afable, Ramon Tiu, Kathy L McGraw, Alan F List and Jaroslaw Maciejewski
    Citation: Journal of Hematology & Oncology 2012 5:4
  23. Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alp...

    Authors: Byung Lee, Nikhil Mukhi and Delong Liu
    Citation: Journal of Hematology & Oncology 2012 5:3
  24. Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) are Chronic Myeloproliferative Neoplasms (MPN) characterized by clonal myeloproliferation/myeloaccumulation without cell maturation impairment. Th...

    Authors: Raquel Tognon, Elainy PL Gasparotto, Renata P Neves, Natália S Nunes, Aline F Ferreira, Patrícia VB Palma, Simone Kashima, Dimas T Covas, Mary Santana, Elizabeth X Souto, Maria Aparecida Zanichelli, Belinda P Simões, Ana Maria de Souza and Fabíola A Castro
    Citation: Journal of Hematology & Oncology 2012 5:2
  25. Speciation of arsenic trioxide (ATO) metabolites in clinical samples such as peripheral blood (PB) from acute promyelocytic leukemia (APL) patients has been conducted. However, speciation of arsenicals in bone...

    Authors: Noriyoshi Iriyama, Yuta Yoshino, Bo Yuan, Akira Horikoshi, Yukio Hirabayashi, Yoshihiro Hatta, Hiroo Toyoda and Jin Takeuchi
    Citation: Journal of Hematology & Oncology 2012 5:1
  26. Infantile hemangiomas (IH) are the most common benign tumors of infancy. The typical clinical course consists of rapid growth during the first year of life, followed by natural and gradual involution over a mu...

    Authors: Dan Xu, Teresa M O, Archil Shartava, Taylor C Fowles, Jianchang Yang, Louis M Fink, David C Ward, Martin C Mihm, Milton Waner and Yupo Ma
    Citation: Journal of Hematology & Oncology 2011 4:54
  27. Dabigatran is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. It has been approved in the European Union and the United States of America for the prevention of thrombosis after...

    Authors: Santiago Redondo, Maria-Paz Martínez, Marta Ramajo, Jorge Navarro-Dorado, Abelardo Barez and Teresa Tejerina
    Citation: Journal of Hematology & Oncology 2011 4:53
  28. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in various tumor cells, but does not affect normal cells or human leukemic cells, such as MOLT-4 and U937 cells, which are rela...

    Authors: Benjawan Wudtiwai, Bungorn Sripanidkulchai, Prachya Kongtawelert and Ratana Banjerdpongchai
    Citation: Journal of Hematology & Oncology 2011 4:52
  29. Although the majority of published cases of lead poisoning come from occupational exposures, some traditional remedies may also contain toxic amounts of lead. Ayurveda is a system of traditional medicine that ...

    Authors: Krishna S Gunturu, Priyadharsini Nagarajan, Peter McPhedran, Thomas R Goodman, Michael E Hodsdon and Matthew P Strout
    Citation: Journal of Hematology & Oncology 2011 4:51
  30. Regulatory T cells (Tregs) are a specialized subpopulation of CD4+ T cells, which act to suppress the activation of other immune cells. Tregs represent important modulators for the interaction between lymphomas a...

    Authors: Jing Wang and Xiao-Yan Ke
    Citation: Journal of Hematology & Oncology 2011 4:50
  31. Most non-Hodgkin's lymphomas (NHL) initially respond to chemotherapy, but relapse is common and treatment is often limited by chemotherapy-related toxicity. Bortezomib, is a highly selective proteasome inhibit...

    Authors: Shiloh M Martin, Eric Churchill, Hayes McKnight, Christopher M Mahaffey, Yunpeng Ma, Robert T O'Donnell and Joseph M Tuscano
    Citation: Journal of Hematology & Oncology 2011 4:49
  32. Regulatory T cells (Treg) that express the transcription factor Foxp3 are enriched within a broad range of murine and human solid tumors. The ontogeny of these Foxp3 Tregs - selective accumulation or prolifera...

    Authors: Jon G Quatromoni, Lilah F Morris, Timothy R Donahue, Yue Wang, William McBride, Talal Chatila and James S Economou
    Citation: Journal of Hematology & Oncology 2011 4:48
  33. Light chain (AL) amyloidosis is a plasma cell dyscrasia characterized by the pathologic production of fibrillar proteins comprised of monoclonal light chains which deposit in tissues and cause organ dysfunctio...

    Authors: Michael Rosenzweig and Heather Landau
    Citation: Journal of Hematology & Oncology 2011 4:47
  34. The regimen of cytarabine, aclarubicin and G-CSF (CAG) has been widely used in China and Japan for treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We searched literature on CAG be...

    Authors: Guoqing Wei, Wanmao Ni, Jen-wei Chiao, Zhen Cai, He Huang and Delong Liu
    Citation: Journal of Hematology & Oncology 2011 4:46
  35. Acute megakaryoblastic leukemia (AMKL) is a type of acute myeloid leukemia (AML), in which majority of the blasts are megakaryoblastic. De novo AMKL in adulthood is rare, and carries very poor prognosis. We he...

    Authors: Xiao Min, Zhang Na, Liu Yanan and Li Chunrui
    Citation: Journal of Hematology & Oncology 2011 4:45
  36. Anti-platelet therapy plays an important role in the treatment of patients with thrombotic diseases. The most commonly used anti-platelet drugs, namely, aspirin, ticlopidine, and clopidogrel, are effective in ...

    Authors: Xuebin Ji and Ming Hou
    Citation: Journal of Hematology & Oncology 2011 4:44
  37. Idiopathic chronic neutropenia (ICN) describes a heterogeneous group of hematologic diseases characterized by low circulating neutrophil levels often associated with recurrent fevers, chronic mucosal inflammat...

    Authors: Roger M Lyons, Sharon T Wilks, Shelby Young and Gail L Brown
    Citation: Journal of Hematology & Oncology 2011 4:43
  38. The MRC UKALLXI trial tested the efficacy of different central nervous system (CNS) directed therapies in childhood acute lymphoblastic leukaemia (ALL). To evaluate morbidity 555/1826 randomised children under...

    Authors: Christina Halsey, Georgina Buck, Sue Richards, Faraneh Vargha-Khadem, Frank Hill and Brenda Gibson
    Citation: Journal of Hematology & Oncology 2011 4:42

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 29.5
    5-year Journal Impact Factor: 26.9
    Source Normalized Impact per Paper (SNIP): 4.489
    SCImago Journal Rank (SJR): 7.522

    Speed 2023
    Submission to first editorial decision (median days): 4
    Submission to acceptance (median days): 59

    Usage 2023
    Downloads: 3,173,795
    Altmetric mentions: 2,671

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here